BGM0504 Injection GLP-1/GIP receptor agonist

share
LinkedIn
Pinterest
Line
Indication Type 2 diabetes mellitus; Obesity
Type Innovative Drug
Form Injection
Target Dual GLP/GIP receptor agonist
Clinical progress Phase Ⅲ clinical trial
Estimated launch time 2027
+86-0571-8875 2329
Reservation Now
Detail

BGM0504 is patent molecular an antidiabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management.


R&D Development:


BGM0504: A Dual Agonist in Clinical Phase Ⅱ


Molecule Design: Novel dual agonist with global patent protection

A.GLP-1R Agonist,confirmed clinical benefits in:

lGlycemic control

lReduced body weight

lImprovement in several cardiovascular risk factors


B.GIPR agonist, potential benefits in:

lMultiple pathways to enhance the efficacy of GLP-1R agonist

lBlocked emesis and attenuates illness-like behaviors elicited by GLP-1R activation.


Pre-clinical Data: Compared to Tirzepatide

Directly compete with Tirzepatide

lcAMP accumulation assay showed that the potency of BGM0504 is approximately 2-fold higher than tirzepatide.

lDemonstrated better efficacy and safety in animal study than tirzepatide. NOAEL values for repeated toxicity were higher than tirzepatide reported.


Clinical Progress: Phase Ⅲ study

lBGM0504 shows superior PK profile compared to tirzepatide in health volunteers with higher exposure.

lBGM0504 shows greater body weight reductions at same close comparing to tirzepatide.

lFinished Phase

lFinished Pharse Ⅱ study and expected to be in Pharse Ⅲ in August 2024.